$55B AbbVie Deal Collapse Boosts Anti-Inversion Campaign

Oct 17, 2014

“Any knock-on effect from the AbbVie board's recommendation against the Shire deal should be limited to other deals similarly structured to access offshore cash and extensively restructure offshore holdings. Many transactions that would not depend on these tax-planning techniques are still good candidates for an inversion.”

- Linda Z. Swartz, Chair of the Tax group at Cadwalader, commenting in Law360 on the effect of the Treasury’s new anti-inversion rules on pending and future inversion transactions.

CadwaladerSpotlight

IMN's 6th Annual Investors' Conference on European CLOs and Leveraged Loans

Nick Shiren and Daniel Tobias will be speaking at this key industry event on April 2 in London.

Cadwalader's research and intelligence platform provides analysis on changes in U.S. financial regulation. Subscribers receive a daily newsletter interpreting new laws, rules and enforcement actions that impact financial institutions.